Analysis of the research, regulation and industrial shifts behind the market numbers.
Record M&A, an actinium-225 bottleneck, a widening FDA approval pathway, and India's fast-scaling nuclear medicine footprint: what is actually moving the radiopharmaceutical industry right now, beyond the market-size headlines.